Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ platform are in late-stage development, with the aim of moving them to full registration under new regulatory frameworks in both the EU and the US. AGY has just announced another solid operating performance and market share gains in its traditionally strong first half, with associated positive cashflow.
16 Jan 2020
Sales growth well above market average
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Sales growth well above market average
Allergy Therapeutics plc (AGY:LON) | 3.0 0 0.0% | Mkt Cap: 143.0m
- Published:
16 Jan 2020 -
Author:
Martin Hall -
Pages:
4
Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ platform are in late-stage development, with the aim of moving them to full registration under new regulatory frameworks in both the EU and the US. AGY has just announced another solid operating performance and market share gains in its traditionally strong first half, with associated positive cashflow.